Chronic rTMS induces subsensitivity of post-synaptic 5-HT1A receptors in rat hypothalamus

International Journal of Neuropsychopharmacology

Volumn 7, Issue 3, 2004, Pages 335-340

  Gur, Eitan ^a   Lerer, Bernard ^a   Van De Kar, Louis D ^b   Newman, Michael E ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

5 HT1A receptor; ACTH; Antidepressant; Corticosterone; Serotonin; Transcranial magnetic stimulation

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; ANTIDEPRESSANT AGENT; CORTICOSTERONE; CORTICOTROPIN; POSTSYNAPTIC RECEPTOR; SEROTONIN 1A AGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN UPTAKE INHIBITOR;

ANIMAL EXPERIMENT; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; CORTICOTROPIN BLOOD LEVEL; DEPRESSION; ELECTROCONVULSIVE THERAPY; HYPOTHALAMUS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR SENSITIVITY; RECEPTOR SUBSENSITIVITY; REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION; TRANSCRANIAL MAGNETIC STIMULATION;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ADRENOCORTICOTROPIC HORMONE; ANIMALS; BRAIN CHEMISTRY; CORTICOSTERONE; ELECTROMAGNETIC FIELDS; HYPOTHALAMUS; MALE; RATS; RATS, WISTAR; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN AGONISTS;

EID: 4444328089     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1461145703003985     Document Type: Article

References (35)

1. Anderson IM, Deakin JFW, Miller HEJ (1996). The effect of chronic fluvoxamine on hormonal and psychological responses to buspirone in normal volunteers. Psychopharmacology 128, 74-82.
2. 2C receptor-mediated oxytocin, prolactin and ACTH/corticosterone responses. Behavioural Brain Research 73, 277-280.
3. 1A receptor agonist-induced corticotropin and cortisol responses after long-term ipsapirone and fluoxetine administration to healthy subjects. Clinical Pharmacology and Therapeutics 63, 428-436.
4. Berman RM, Narasimhan M, Sanacora G, Miano AP, Hoffman RE, Hu XS, Charney DS, Boutros NN (2000). A randomized clinical trial of repetitive transcranial magnetic stimulation in the treatment of major depression. Biological Psychiatry 47, 332-337.
5. Blier P, de Montigny C (1994). Current advances and trends in the treatment of depression. Trends in Pharmacological Sciences 15, 220-226.
6. Blier P, de Montigny C (1998). Possible serotonergic mechanisms underlying the antidepressant and anti-obsessive-compulsive disorder responses. Biological Psychiatry 44, 313-323.
7. Burt T, Lisanby SH, Sackeim HA (2002). Neuropsychiatric applications of transcranial magnetic stimulation: a meta-analysis. International Journal of Neuropsychopharmacology 5, 73-103.
8. Czeh B, Welt T, Fischer AK, Erhardt A, Schmitt W, Muller MB, Toschi N, Fuchs E, Keck ME (2002). Chronic psychosocial stress and concomitant repetitive transcranial magnetic stimulation: effects on stress hormone levels and adult hippocampal neurogenesis. Biological Psychiatry 52, 1057-1065.
9. Dannon P, Dolberg O, Schreiber S, Grunhaus L (2002). Three-and six-month outcome following courses of either ECT or rTMS in a population of severely depressed individuals - preliminary report. Biological Psychiatry 51, 687-690.
10. Fleischmann A, Prolov K, Abarbanel J, Belmaker RH (1995). The effect of transcranial magnetic stimulation of rat brain on behavioral models of depression. Brain Research 699, 130-132.
11. George MS, Wassermann EM, Williams WA, Steppel J, Pascual-Leone A, Basser P, Hallett M, Post RM (1996). Changes in mood and hormone levels after rapid-rate transcranial magnetic stimulation (rTMS) of the prefrontal cortex. Journal of Neuropsychiatry and Clinical Neuroscience 8, 172-180.
12. George MS, Nahas Z, Molloy M, Speer AM, Oliver NC, Li X-B, Arana GW, Risch SC, Ballenger JC (2000). A controlled trial of daily left prefrontal cortex TMS for treating depression. Biological Psychiatry 48, 962-970.
13. Grisaru N, Yeroslavsky U, Abarbanel J, Lamber T, Belmaker RH (1994). Transcranial magnetic stimulation in depression and schizophrenia. Europeon Neuropsychopharmacology 4, 287-288.
14. Grunhaus L, Dannon P, Schreiber S, Dolberg OH, Amiaz R, Ziv R, Lefkifker E (2000). Repetitive transcranial magnetic stimulation is as effective as electroconvulsive therapy in the treatment of nondelusional major depressive disorder: an open study. Biological Psychiatry 47, 314-324.
15. 1B receptor activity in rat hippocampus and hypothalamus. Brain Research 952, 52-60.
16. Gur E, Dremencov E, Van de Kar LD, Lerer B, Newman ME (2002a). Effects of chronically administered venlafaxine on 5-HT receptor activity in rat hippocampus and hypothalamus. European Journal of Pharmacology 436, 57-65.
17. Gur E, Lerer B, Dremencov E, Newman ME (2000). Chronic repetitive transcranial magnetic stimulation induces subsensitivity of presynaptic serotonergic autoreceptor activity in rat brain. Neuroreport 11, 2925-2929.
18. Janicak PG, Dowd SM, Martis B, Alam D, Beedle D, Krasuki J, Strong MJ, Sharma R, Rosen C, Viana M (2002). Repetitive transcranial magnetic stimulation versus electroconvulsive therapy for major depression: preliminary results of a randomized trial. Biological Psychiatry 51, 659-667.
19. Keck ME, Welt T, Post A, Muller MB, Toschi N, Wigger A, Landgraf R, Holsboer F, Engelmann M (2001). Neuroendocrine and behavioral effects of repetitive transcranial magnetic stimulation in a psychopathological animal model are suggestive of antidepressant-like effects. Neuropsychopharmacology 24, 337-349.
20. Klein E, Kreinin I, Chistyakov A, Koren D, Mecz L, Marmur S, Ben-Shachar D, Feinsod M (1999). Therapeutic efficacy of right prefrontal slow repetitive transcranial magnetic stimulation in major depression. Archives of General Psychiatry 56, 315-320.
21. 1A receptor function in normal subjects on clinical doses of fluoxetine: blunted temperature and hormone responses to ipsapirone challenge. Neuropsychopharmacology 20, 628-639.
22. 1A receptor responsivity in obsessive-compulsive disorder. Psychopharmacology 105, 415-420.
23. Levkovitz Y, Grisaru N, Segal M (2001). Transcranial magnetic stimulation and antidepressive drugs share similar cellular effects in rat hippocampus. Neuropsychopharmacology 25, 608-616.
24. 1A agonist, ipsapirone, by long-term treatment with fluoxetine, but not desipramine, in male rats. Biological Psychiatry 36, 300-308.
25. 1A agonist, 8-OH-DPAT, in male rats. Brain Research 630, 148-156.
26. 1A receptors. Journal of Pharmacology and Experimental Therapeutics 282, 1581-1590.
27. 1A agonist. Journal of Pharmacology and Experimental Therapeutics 279, 1035-1042.
28. Lisanby SH, Luber B, Perera T, Sackeim HA (2000). Transcranial magnetic stimulation: applications in basic neuroscience and neuropharmacology. International Journal of Neuropsychopharmacology 3, 259-273.
29. 1A receptor labeling in mice selected as a genetic model of helplessness. Brain Research 936, 68-75.
30. Post A, Keck ME (2001). Transcranial magnetic stimulation as a therapeutic tool in psychiatry: What do we know about the neurobiological mechanisms? Journal of Psychiatric Research 35, 193-215.
31. Pridmore S, Bruno R, Turnier-Shea Y, Reid P, Rybak M (2000). Comparison of unlimited numbers of rapid transcranial magnetic stimulation (rTMS) and ECT treatment sessions in major depressive episode. International Journal of Neuropsychopharmacology 3, 129-134.
32. 1A receptor sensitivity. Psychopharmacology 132, 296-302.
33. 35S] GTPγS binding in rat brain regions. Neuropharmacology 42, 1031-1038.
34. Szuba M, O'Reardon JP, Rai AS, Snyder-Kastenberg J, Amsterdam JD, Gettes DR, Wassermann E, Evans DL (2001). Acute mood and thyroid stimulating hormone effects of transcranial magnetic stimulation in major depression. Biological Psychiatry 50, 22-27.
35. Zhang Y, Raap DK, Garcia F, Serres F, Ma Q, Battaglia G, Van de Kar LD (2000). Long-term fluoxetine produces behavioral anxiolytic effects without inhibiting neuroendocrine responses to conditioned stress in rats. Brain Research 855, 58-66.